Tb guidelins
Reading File
Finding Sources
Searching PubMed
"tuberculosis"[MeSH Terms] AND "treatment guidelines"
Searching the Web
WHO tuberculosis treatment guidelines 2025 2026
Finding Sources
Reading Web Page
https://www.eatg.org/hiv-news/who-announces-landmark-changes…
Finding Sources
Reading File
Reading File
Reading File
Reading File
Here is a comprehensive summary of current TB treatment guidelines, incorporating the latest 2024–2025 updates from WHO, ATS/CDC/ERS/IDSA, and standard textbook recommendations.
Tuberculosis (TB) Treatment Guidelines
1. Latent TB Infection (LTBI)
Goal: prevent progression to active disease. Preferred regimens (Goldman-Cecil Medicine):
| Regimen | Duration | Dosing |
|---|---|---|
| Isoniazid (H) + Rifapentine (P) | 3 months | Once weekly |
| Rifampin (R) alone | 4 months | Daily |
| Isoniazid + Rifampin | 3 months | Daily |
| Isoniazid alone | 6 months | Daily |
| Isoniazid alone | 9 months | Daily |
Pyridoxine (Vitamin B6) 25–50 mg/day should be co-administered with isoniazid in all patients at risk of neuropathy (elderly, pregnant, malnourished, diabetic, HIV+, alcohol use).
2. Drug-Susceptible TB (DS-TB) — Active Disease
Standard 6-Month Regimen (Classic)
- Intensive phase (2 months): Isoniazid (H) + Rifampin (R) + Pyrazinamide (Z) + Ethambutol (E) — HRZE
- Continuation phase (4 months): Isoniazid + Rifampin — HR
This is the preferred regimen for newly diagnosed pulmonary TB.
🆕 NEW 4-Month Regimen (ATS/CDC/ERS/IDSA, December 2024)
The updated ATS/CDC/ERS/IDSA guideline (published Dec 31, 2024) now recommends:
- Adults & adolescents ≥12 years: 2HPZM / 2HPM
- 2 months of Isoniazid + Rifapentine + Pyrazinamide + Moxifloxacin, then
- 2 months of Isoniazid + Rifapentine + Moxifloxacin
- Children 3 months–16 years (non-severe TB): 2HRZE / 2HR (4 months total)
3. Drug-Resistant TB
MDR-TB / RR-TB (Resistant to Isoniazid + Rifampin)
🆕 WHO Consolidated Guidelines, Module 4 (April 2025) introduced a landmark update:
BDLLfxC Regimen (NEW, 6 months, all-oral)
- Bedaquiline + Delamanid + Linezolid + Levofloxacin + Clofazimine
- Recommended for MDR/RR-TB with or without additional fluoroquinolone resistance (pre-XDR-TB)
- Replaces longer regimens previously lasting 9–20 months
BPaLM Regimen (Established, 6 months)
- Bedaquiline + Pretomanid + Linezolid + Moxifloxacin
- Validated in TB PRACTECAL trial — noninferior to standard care with fewer serious adverse events
- WHO-recommended since 2022 guidelines update
BPaL Regimen (XDR-TB / treatment-intolerant)
- Bedaquiline + Pretomanid + Linezolid (Nix-TB study)
- 90% favorable outcomes in XDR-TB
- Higher adverse events (mainly linezolid toxicity)
Modified 9-Month Regimen
- Still recommended where fluoroquinolone resistance is excluded
- Used in settings where newer drugs are unavailable
Key shift: Kanamycin and capreomycin are no longer recommended due to increased toxicity and worse outcomes (per individual patient-level meta-analysis).
Pre-XDR-TB and XDR-TB
Defined as MDR/RR-TB + resistance to any fluoroquinolone (pre-XDR) or additional resistance to bedaquiline/linezolid (XDR). Managed with BPaLM or BPaLM-variant regimens under specialist supervision.
4. Special Populations
| Population | Consideration |
|---|---|
| HIV co-infection | Start ART within 2 weeks of TB treatment; same duration as HIV-negative; similar sputum conversion rates |
| TB meningitis | Add corticosteroids (dexamethasone); mortality ~25% (HIV+: ~50%) even with treatment |
| Pregnancy | Avoid pyrazinamide in some guidelines; rifampin is safe; isoniazid + pyridoxine |
| Children | Weight-based dosing; non-severe disease may qualify for 4-month regimen |
| Renal impairment | Reduce aminoglycoside doses; avoid kanamycin/capreomycin |
5. Directly Observed Therapy (DOT)
DOT remains the standard of care — a healthcare worker observes ingestion of medication, particularly for twice-weekly regimens and MDR-TB treatment.
6. Monitoring & Outcomes
- After 2 weeks of effective treatment: 99.9% decline in bacterial colony counts; patient becomes non-infectious
- Drug-susceptible TB cure rate: ~100% with completed treatment
- MDR-TB cure rate: 50–60%
- XDR-TB cure rate: 2–22% (improving with new regimens; BPaLM achieving ~90%)
- Global treatment success: 85%; US: 95%
Summary of Key 2024–2025 Changes
| Update | Source | Change |
|---|---|---|
| 4-month regimen for DS-TB | ATS/CDC/ERS/IDSA (Dec 2024) | 2HPZM/2HPM replaces 6-month for eligible adults |
| BDLLfxC for MDR/RR-TB | WHO Module 4 (Apr 2025) | New all-oral 6-month regimen, even for pre-XDR |
| TB + undernutrition | WHO Module 6 (Oct 2025) | Food assistance for household contacts in food-insecure settings |
| AI screening | 2026 guidelines | AI chest X-ray reading with sensitivity exceeding human experts; "X-ray for any cough" |
Sources: Harrison's Principles of Internal Medicine 22E (2025); Goldman-Cecil Medicine; ATS/CDC/ERS/IDSA Clinical Practice Guideline (Dec 2024); WHO Consolidated Guidelines on TB, Module 4 (Apr 2025); WHO Module 6 (Oct 2025)
This is a shared conversation. Sign in to Orris to start your own chat.